Glaukos Co. (NYSE:GKOS) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. cut its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 86.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,398 shares of the medical instruments supplier's stock after selling 150,000 shares during the period. Adage Capital Partners GP L.L.C.'s holdings in Glaukos were worth $3,508,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in GKOS. IFP Advisors Inc acquired a new stake in Glaukos in the fourth quarter valued at approximately $43,000. Asset Planning Inc purchased a new position in Glaukos in the fourth quarter valued at $90,000. Picton Mahoney Asset Management purchased a new position in Glaukos in the fourth quarter valued at $125,000. SBI Securities Co. Ltd. acquired a new stake in Glaukos in the fourth quarter valued at $153,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock worth $164,000 after buying an additional 807 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Insiders Place Their Bets

In related news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Glaukos Price Performance

Shares of GKOS stock traded down $1.45 during trading hours on Monday, hitting $86.17. The company's stock had a trading volume of 358,555 shares, compared to its average volume of 944,181. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The stock has a market cap of $4.92 billion, a price-to-earnings ratio of -29.99 and a beta of 0.88. The business has a fifty day moving average of $97.60 and a 200-day moving average of $128.81.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. The company had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business's revenue for the quarter was up 24.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.70) earnings per share. As a group, equities research analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on GKOS. Truist Financial reissued a "buy" rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a report on Thursday. Needham & Company LLC reduced their price target on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $160.00 to $86.00 in a report on Thursday. Stephens decreased their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday. Finally, Stifel Nicolaus lowered their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and an average target price of $137.62.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.